28
Oct
2025

Brightlabs

Exhibitor at CPHI Frankfurt 2025 stand 5.0A75, Contract Manufacturing and Services
About Us

Brightlabs is the laboratory for all analytical matters for the pharmaceutical industry. It is our mission to help our customers with their pharmaceutical development and validation projects. For this, Brightlabs has a broad range of equipment available (eg LC-MS/MS, LC-UV, LC-CAD, GC-MS/MS, GC-FID). Brigtlabs focus is on:
Method Development & Validation
Stability Study
Contaminants (i.e. Elemental Impurities & Nitrosamines)
Starting Materials
Microbiology

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • NL
  • 2021
    On CPHI since
  • 2
    Certificates
  • 25 - 49
    Employees
Company types
Contract Service
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI Frankfurt 2025
  • 28 Oct 2025 - 30 Oct 2025
  • Messe, Frankfurt
  • Visit us at stand 5.0A75, Contract Manufacturing and Services

Products Featured at CPHI Frankfurt 2025

  • Elemental Impurities

    Product Elemental Impurities

    Brightlabs has in-house validated methods for the analysis of elemental impurities in accordance to ICH-Q3D. Brightlabs has a unique approach for ICHQ3D, which guarantees quick turnaround times at reduced cost
  • Herbal Drugs Analysis

    Product Herbal Drugs Analysis

    Since 2018 Brightlabs possesses an opium exemption from the BMC (Bureau for Medicinal Cannabis), for the analysis of cannabis and related products. The combination of this opium exemption, combined with our GMP accreditation, makes Brightlabs an important partner for the analysis of cannabis and related ma...
  • Method Development

    Product Method Development

    We are specialist in the method development of analytical methods for analysis of API, Final Drug Products or low level impurities. Usually followed by full validation in accordance to ICH guidelines.
  • Nitrosamine Analysis

    Product Nitrosamine Analysis

    In response to nitrosamines present in pharmaceutical products, the European Medical Agency (EMA) and the US Food and Drug Administration (US FDA) have published requirements and limits related to nitrosamine contaminants. Therefore Brightlabs has developed and validated multiple methods to determine low l...